about
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Venous thromboembolism and cancer: new issues for an old topic.Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tractModulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen aloneBisphosphonates and metastatic bone disease.From the trastuzumab era to new target therapies: beyond revolution.Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.Gene expression profiling in breast cancer: a clinical perspective.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.Metronomic chemotherapy for advanced breast cancer patients.Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers.Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.Adjuvant systemic treatment of early breast cancer: the NORA study.A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.In reply to Kadri Altundag.Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter StudyLong-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up studyIncidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancerAcute dyspnea due to right phrenic palsy during infusional chemotherapyPrediction of recurrence in operable breast cancer by postoperative changes in prolactin secretionA randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folatesAcute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA studyThe extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinomaPan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
P50
Q34492429-02CDF13C-80C7-4720-A42A-7F9D4A8C69FDQ35571461-7739F2AA-C16D-4E7D-A099-8C2869D498F0Q35977112-428AA168-D09F-4B6F-B57D-7501646D4BC7Q36080730-90B9EAA8-C136-42F3-A9EB-F885DB619775Q36445894-07D5F9D8-806E-4223-AAD6-FDD562D1A137Q36860119-6C57F310-BAFC-445E-8B1F-4A31720F2ED3Q37151612-D4492BEE-A70F-4511-8C07-9D3685260E30Q37385672-EE9CB709-BF6A-4620-AC77-EE246218112AQ38086710-F9D3EA2D-61E6-49ED-BD55-EF19FF4BDD5DQ38638654-E152EA44-AC79-4937-8B75-3D423D743EA0Q38677321-6A55B481-9713-49E8-A3D0-751FC467FAE3Q38825756-861F5448-AF7D-4E06-B9D8-882154F653D1Q38862060-A59A61EE-E781-4AD3-9D96-2D4F8887146DQ39054743-074EDFC2-E73B-484B-AC53-2AB0A016D644Q39372626-7688E722-7649-4C8E-92EE-B5E30DEAC996Q40359525-43B27235-2607-46DA-9372-D95633F707BDQ40566086-BD966FB0-4F42-4D95-A85D-61A6CA16A2E5Q41095276-00767682-72FC-4AB3-9B45-87F779DD7112Q42876427-229CDF5F-05FF-412E-912C-067715E95758Q43446697-138620F1-3272-4BCC-8EBA-FBE618F33ACEQ44791732-0FADC3A3-190E-44A7-A64D-AB12E6B7F795Q46158825-71519C69-AD2A-4251-8243-C96A08E482CAQ47732726-2FD0E24C-43EA-4C82-A224-550F3AE79BB3Q48349326-5C6301BA-EE85-4837-942A-7CC506B2FC1AQ53253818-A78F0D9C-9575-4454-8013-A66B21F2AD01Q53644178-B5773993-D8F2-4851-ACC6-A3555FC17923Q53780402-0243C591-AAD5-48C9-AC62-4BA2B2A5FD8DQ53824674-4764E54E-1994-49D3-8238-61B4766849C0Q54180020-B7BD6319-15C4-4F69-A568-227C9C47FC47Q54199692-2E8DD7FA-BCBD-4066-B15B-22BCD8B8D4D8Q57758305-236EAAF9-8B40-4837-9499-07A457446864Q58874339-106985B9-9C10-46B2-B019-05D0A64B56CBQ58874370-A80A16E6-8CEC-4A9A-8720-B01359F20186Q59698134-CBCE9627-DE05-4883-A559-E7D2684A6768Q71526577-E188095B-7756-4A4E-8862-490E91F35913Q72154031-9B10DD88-1531-46CB-9A1D-EBD952A75873Q73307133-7C4B334D-F100-4509-A947-AC0B73D78BF6Q80970109-128330F8-B629-433D-8ED4-BD45A1EB9633Q83120450-B33CD881-0BC5-4060-B010-CEE2BB5B3FA1Q90627608-C8E98D50-3EF5-4A8B-B90A-F3D6E8D5016C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marina Elena Cazzaniga
@ast
Marina Elena Cazzaniga
@en
Marina Elena Cazzaniga
@es
Marina Elena Cazzaniga
@nl
type
label
Marina Elena Cazzaniga
@ast
Marina Elena Cazzaniga
@en
Marina Elena Cazzaniga
@es
Marina Elena Cazzaniga
@nl
prefLabel
Marina Elena Cazzaniga
@ast
Marina Elena Cazzaniga
@en
Marina Elena Cazzaniga
@es
Marina Elena Cazzaniga
@nl
P106
P1153
57190110013
P21
P31
P496
0000-0003-1756-6935